WCN26-3894 HS-10542, A ONCE-DAILY NOVEL SMALL-MOLECULE FACTOR B INHIBITOR, IN HEALTHY CHINESE PARTICIPANTS: A FIRST-IN-HUMAN PHASE 1 TRIAL

Read full text Summarise with VIRAT
Authors: Chenjing Wang, Yi Xu, Feifei Sun, Lin Fang, Yusong Zhu, Jian Yang, Ran Liu, Wei Liu, X. Zhang, Yu Cao
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

An over-active alternative complement pathway has been implicated in the pathophysiology of multiple diseases, including paroxysmal nocturnal hemoglobinuria and IgA nephropathy. HS-10542 is a once-daily oral selective small-molecule inhibitor of complement factor B, a key component of the alternative pathway. This first-in-human study assessed the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HS-10542 in healthy Chinese participants.

Fields of Study & Subjects

Complement system in diseases Coagulation Bradykinin Polyphosphates and Angioedema Renal Diseases and Glomerulopathies

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106210–106210
Publication date
25 March 2026
Language
EN